Home » Stocks » XBiotech

XBiotech Inc. (XBIT)

Stock Price: $18.12 USD -0.19 (-1.04%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 525.28M
Revenue (ttm) 28.18M
Net Income (ttm) 673.49M
Shares Out 28.99M
EPS (ttm) 15.24
PE Ratio 1.19
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $18.12
Previous Close $18.31
Change ($) -0.19
Change (%) -1.04%
Day's Open 18.16
Day's Range 17.76 - 18.65
Day's Volume 107,756
52-Week Range 8.72 - 26.40

More Stats

Market Cap 525.28M
Enterprise Value 295.58M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.99M
Float 14.49M
EPS (basic) 17.25
EPS (diluted) 15.24
FCF / Share -2.84
Dividend n/a
Dividend Yield n/a
Earnings Yield 84.11%
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.77M
Short Ratio 10.51
Short % of Float 12.20%
Beta 1.50
PE Ratio 1.19
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 18.64
PB Ratio 1.53
Revenue 28.18M
Operating Income -28.11M
Net Income 673.49M
Free Cash Flow -81.95M
Net Cash 229.70M
Net Cash / Share 7.92
Gross Margin 18.80%
Operating Margin -99.74%
Profit Margin 2,390.00%
FCF Margin -290.83%
ROA -8.16%
ROE 326.16%
ROIC 1,004.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$18.00*
Low
18.0
Current: $18.12
High
18.0
Target: 18.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-31.23-20.99-34.06-52.76-37.51-21.78-9.93-15.16
Net Income669-21.14-33.15-52.76-37.48-21.72-9.93-15.16
Shares Outstanding38.9535.8034.8832.4030.8024.1622.2221.29
Earnings Per Share14.44-0.59-0.95-1.63-1.22-0.90-0.45-0.71
Operating Cash Flow-18.27-16.54-33.65-46.02-33.31-11.70-8.91-11.63
Capital Expenditures-0.20-0.12-1.41-13.91-10.39-1.40-0.06-0.55
Free Cash Flow-18.47-16.66-35.05-59.93-43.70-13.10-8.97-12.18
Cash & Equivalents71515.8231.7734.3291.0557.337.24-
Net Cash / Debt71515.8231.7734.3291.0557.337.24-
Assets81744.3562.9767.0510962.1811.07-
Liabilities61.252.952.817.996.313.150.85-
Book Value75641.4060.1659.0610359.0310.23-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name XBiotech Inc.
Country United States
Employees 78
CEO John Simard

Stock Information

Ticker Symbol XBIT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XBIT
IPO Date April 15, 2015

Description

XBiotech, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.